Search results
Results from the WOW.Com Content Network
Natalizumab, sold under the brand name Tysabri among others, is a medication used to treat multiple sclerosis and Crohn's disease. [9] It is a humanized monoclonal antibody against the cell adhesion molecule α4-integrin. [9] It is given by intravenous infusion. [9]
New TYSABRI ® Data Show Earlier Treatment and Longer-Term Use Result in Significant Reductions in MS Disease Activity - Earlier Treatment with TYSABRI Demonstrated Reduction in Relapse Severity ...
TYSABRI ® (natalizumab) Data at ECTRIMS Reaffirm Positive Effects of Treatment for People with Relapsing Forms of MS -- Data demonstrate TYSABRI effect on Annualized Relapse Rates and EDSS scores ...
ADDING MULTIMEDIA New TYSABRI Data Reaffirm Substantial Efficacy in Treatment of People with MS and Demonstrate Stability of Anti-JCV Antibody Status - Continued Research into Risk Stratification ...
Ocrelizumab, sold under the brand name Ocrevus, is a medication used for the treatment of multiple sclerosis. It is a humanized anti-CD20 monoclonal antibody. [8] It targets CD20 marker on B lymphocytes and is an immunosuppressive drug. [10] Ocrelizumab binds to an epitope that overlaps with the epitope to which rituximab binds. [10]
Fingolimod (Gilenya), an oral treatment and the first oral therapy approved for multiple sclerosis. Siponimod (Mayzent), oral. Approved in March 2019 for CIS, RRMS and SPMS [11] [12] Ozanimod: oral. It was approved by the FDA in March 2020 with the trade name Zeposia [13] [14] [15] Ponesimod (Ponvory) Five monoclonal antibodies: Alemtuzumab ...
See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page. This is a dynamic list and may never be able to satisfy particular standards for completeness. You can help by adding missing items with reliable sources .
The advantage of active monoclonal antibody therapy is the fact that the immune system will produce antibodies long-term, with only a short-term drug administration to induce this response. However, the immune response to certain antigens may be inadequate, especially in the elderly.